PYC
data caveat$1.3B26mo
PYC Therapeutics
Biotech · RNA therapeutics
Precision RNA therapeutics for genetic diseases, lead program VP-001 for retinitis pigmentosa
Data HealthTrials5 of 5 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$120.7M
Dec 2025 4C
Runway
26moSTABLE
Based on Dec 2025 4C
Market Cap
$1.3B
Burn Rate
$13.8M/qtr
Dec 2025 4C
Shares Outstanding
983M
Pipeline Assets
2
Latest Insight(1)
1 Apr 2026substantial_holderChange in substantial holding
Changed·AUSTRALIAN LAND PTY LTD & OTHER ENTITIES ASSOCIATED WITH MR ALAN TRIBE·18.99%
3M Price
PYC.ASX$1.285-22.8% 3M
Low $1.065High $1.685
Pipeline Assets (2)
VP-002Huntington disease
PreclinicalVP-001Retinitis pigmentosa type 11
Phase 1/2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
VP-002
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
4 transactionsLast 90dNet Buy
Buys4+4 vs prior
Sells0
Buy Value$504k
warning2 directors bought within 30 days (03-06 – 03-24) — $504k total
$99,8832026-03-24
9d after ·
Substantial Holders (5%+ threshold)
2 noticesarrow_drop_downAUSTRALIAN LAND PTY LTD & OTHER ENTITIES ASSOCIATED WITH MR ALAN TRIBE
18.99%2026-03-31
arrow_drop_downAUSTRALIAN LAND PTY LTD & OTHER ENTITIES ASSOCIATED WITH MR ALAN TRIBE
18.99%2026-03-31
Director Options & Rights
4,000,000 outstanding
Director
Outstanding
Ex. Price
Expiry
Dr Rohan HockingsoutstandingOptions
50% vests 12 months from issue date, 50% vests 24 months from issue date
1,500,000
outstanding
$2.520
-49%
no expiry
Dr Rohan HockingsoutstandingOptions
50% vests at 12 months from date of issue, 50% vests at 24 months from date of issue. Subject to shareholder approval. Exercisable within 48 months from date of issue.
1,500,000
outstanding
$2.520
-49%
no expiry
Professor Ian ConstableoutstandingOptions
50% vests at 12 months from date of issue, 50% vests at 24 months from date of issue. Subject to shareholder approval. Exercisable within 48 months from date of issue.
1,000,000
outstanding
$1.800
-29%
no expiry
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.05%
arrow_drop_down-0.13% over 30 reports
Shares short
0.5M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
19 competitor trialsPhase 2+ · Non-ASX
Huntington Disease19 active trials
3 Ph34 Ph2/35 Ph27 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 3 upcoming · 1 past
VP-001 Phase 1/2 RP11 further data
UpcomingExpectedarrow_upwardHigh30 June 2026
SpeculativeremoveMed1 Dec 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High91/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 12% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 97% of opex directed to R&D
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(8)
5 activeClinicalTrials.gov ↗
Ph1RecruitingEnrollment stale · 380d
PYC-003
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RandomizedTriple Blind18 Years – 65 Years
Primary endpoint [Part A, B and C] Number of participants experiencing treatment emergent adverse events (AE) as assessed by CTCAE V5.0
Ph1/PHASE2RecruitingEnrollment stale · 204d
PYC-001
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
OPA1 Gene Mutation · Autosomal Dominant Optic Atrophy · Hereditary Optic Atrophies +1 more
RandomizedOpen Label18 Years+
Primary endpoint [All Cohorts] Number of participants experiencing treatment emergent adverse events
Ph1/PHASE2RecruitingEnrollment stale · 325d
VP-001
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Retinitis Pigmentosa 11 · Retinal Degeneration · Retinal Disease +2 more
18 Years+
Primary endpoint To determine the safety of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy.